Related Experiment Videos
c-jun oncogene expression in transitional cell carcinoma of the urinary bladder
D G Tiniakos1, K Mellon, J J Anderson
1Department of Pathology, School of Pathological Sciences, University of Newcastle upon Tyne, UK.
British Journal of Urology
|December 1, 1994
Summary
C-jun oncoprotein is highly expressed in most bladder cancers (transitional cell carcinomas). Its expression correlates with advanced tumor stage and EGFR positivity, but not patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Uropathology
Background:
- Transitional cell carcinoma (TCC) is the most common type of bladder cancer.
- Oncoproteins like c-jun play roles in cell proliferation and differentiation.
- Understanding oncoprotein expression aids in predicting tumor behavior.
Purpose of the Study:
- To assess c-jun oncoprotein expression in TCCs.
- To correlate c-jun expression with tumor grade, stage, and other oncoproteins (EGFR, c-erbB-2, p53).
Main Methods:
- Immunohistochemistry was used to detect c-jun expression.
- The study analyzed 48 TCC tissue samples.
- EGFR, c-erbB-2, and p53 status were known for the samples.
Main Results:
- 92% of TCCs (44/48) exhibited c-jun nuclear immunoreactivity.
- Higher c-jun expression intensity was significantly linked to advanced tumor stage (P=0.009) and EGFR positivity (P=0.01).
- No significant correlation was found between c-jun expression and c-erbB-2, p53, patient survival, or recurrence rates.
Conclusions:
- C-jun oncoprotein is frequently expressed in bladder TCCs.
- Intense c-jun expression is associated with muscle-invasive growth and EGFR positivity in TCCs.